Chloroquine and hydroxychloroquine for treating COVID-19: benefits and harms are uncertain
Citation: Gbingie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open 2020; bjgpopen20X101069 [Epub ahead of print 7 April 2020]
What is this? A variety of drugs are being assessed as possible treatments for COVID-19. These include chloroquine and hydroxychloroquine.
In this rapid review, the authors searched for in vitro studies, in vivo studies and literature reviews on the effects of chloroquine and hydroxychloroquine against the virus, SARS-CoV-2 and for treating patients with COVID-19. They did not restrict their search by date, type or language of publication, and did their most recent search on 28 March 2020. They identified three laboratory-based studies and three reports of the treatment of patients with COVID-19. These reports were a news briefing from 10 hospitals in China (chloroquine), a randomized trial in China (hydroxychloroquine) and a non-randomised controlled trial in France (hydroxychloroquine with azithromycin).
What works: Nothing noted.
What doesn’t work: Nothing noted.
What’s uncertain: At the time of the review (March 2020), although laboratory-based studies had reported antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2, the available evidence on the effectiveness of these drugs for treating COVID-19 patients was very limited and the potential benefits and harms were uncertain.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone. The text can be shared and re-used without charge, citing Evidence Aid as the source and noting the date on which you took the text.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.